Navigation Links
Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:10/3/2011

ound at www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release and the conference call that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding: the use of validated models to predict the long-term risk of CV disease, CV mortality, myocardial infarction and stroke with Contrave and the potential impact of long-term treatment with Contrave; the ability of such models to predict the successful outcome of a cardiovascular outcomes trial; the ability for Contrave to enhance the activation of brain regions following exposure to food cues to help patients control food cravings; the study design for, and the timing and feasibility of, the CVOT; the potential for resubmission and approval of an NDA based on interim results of the CVOT; the potential for Contrave to effectively treat obesity; and the prospects for ultimate approval of an NDA for Contrave.The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ from those set forth in this release and the conference call due to the risk and uncertainties inherent in Orexigen's business, including, without limitation: Orexigen's ability to maintain and raise sufficient capital to fund the CVOT and maintain its other operations; the uncertainty of the FDA approval process, including requirements for additional clinical and non-clinical studies or other commitments prior to the resubmission and approval of an NDA f
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Institute for Clinical Research, Inc., a clinical research organization ... new textbook,  Translational Research Methods for Diabetes, Obesity and ... scientific publisher. The textbook is the first ... early phase clinical studies of new drugs for diabetes, ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has ... Allergen Source, Product & by End User - Global Forecast ... The global allergy diagnostics market is valued at $1,228.58 million ... of 12.67%, to reach $2,230.72 million by 2019. Allergy diagnostics ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... , PARSIPPANY, N.J., Oct. 29 Ferring Pharmaceuticals Inc. ... Associate Medical Director for Orthopaedics. Dr. Kovelman will ... sodium hyaluronate), a treatment for knee pain due to ... products. , "Dr. Kovelman is exceptionally well qualified to ...
... Cempra Pharmaceuticals today announced a presentation on its ... of America, 47th Annual Meeting, October 29 to November ... more than 25 other antibiotics was tested against 1,737 ... from medical centers in the U.S., Europe and Latin ...
Cached Medicine Technology:Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 2Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 3Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates 2
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... The most common indication worldwide for pediatric transplantation, biliary ... liver disease in newborns. Recently, Childrens Hospital of Pittsburgh ... children with biliary atresia face that lead to the ... of children undergoing their first liver transplant are diagnosed ...
... Washington University School of Medicine in St. Louis have ... proteins associated with the formation of actin networks, which ... to move is important to a broad range of ... disease-causing invaders and how metastasizing cancer cells migrate from ...
... What: , The AACR Annual Meeting features the ... cancer research. This years meeting focuses on ... pipeline, clinical trials, and new approaches to cancer ... of the meeting, the program schedule and related ...
... Workout ... Jude Children,s Research ... Hospital(R), FORT LAUDERDALE, Fla., Jan. 8 ... Ab Crunch Challenge,a fitness challenge that will benefit your waistline and is expected ...
... Pa., Jan. 8 Isolagen(TM), Inc. (Amex: ILE ... Declan Daly,Chief Executive Officer of Isolagen, will present at ... 2008 at 2:00 p.m.,(Pacific Time) / 11:00 a.m. (Eastern ... Francis Hotel in San Francisco, California., The presentation ...
... Top Five New York State Hospitals, ... (OTC Bulletin Board: GLOB), an international e-Health, ... Wyndgate,Technologies(R) division has signed a purchase agreement ... New York for its,advanced transfusion management software, ...
Cached Medicine News:Health News:Children's Hospital physicians publish review of transplant issues in patients with biliary atresia 2Health News:Insights into cell movement likely to aid immune study, cancer research 2Health News:Insights into cell movement likely to aid immune study, cancer research 3Health News:Get a Six Pack While Giving Back 2Health News:Get a Six Pack While Giving Back 3Health News:Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference 2Health News:Global Med Technologies(R) Adds Eighth SafeTrace Tx(R) Client in New York State 2Health News:Global Med Technologies(R) Adds Eighth SafeTrace Tx(R) Client in New York State 3
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Fome-Cuf® Oral/Nasal Wire Reinforced Endotracheal ... kit is packaged individually and includes ... Maintenance Device (CMD™), and 15 mm ... provides maximum patient safety by helping ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
... Ruschelit® PVC. 2 eyes, oral. Marked ... age. X-ray opaque line. Graduated. Single ... Designed to reduce kinking of the ... Thermosensitive Ruschelit® PVC adapts to the ...
Medicine Products: